UGT2A2

Chr 4

UDP glucuronosyltransferase family 2 member A2

Also known as: UDPGT 2A2

The encoded UDP-glucuronosyltransferase catalyzes the conjugation of lipophilic substrates with glucuronic acid to facilitate their excretion, playing a key role in detoxification of drugs, xenobiotics, and endogenous compounds including estradiol and bile acids. The gene is not constrained against loss-of-function variants, and polymorphisms have been associated with loss of taste and smell during SARS-CoV-2 infection, but established Mendelian disease associations in pediatric populations are not well-documented.

OMIMResearchSummary from RefSeq, UniProt
MultiplemechanismLOEUF 1.38
Clinical SummaryUGT2A2
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
22 unique Pathogenic / Likely Pathogenic· 50 VUS of 86 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.38LOEUF
pLI 0.000
Z-score 0.17
OE 0.96 (0.681.38)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
-1.70Z-score
OE missense 1.29 (1.181.41)
358 obs / 278.1 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios
LoF OE0.96 (0.681.38)
00.351.4
Missense OE1.29 (1.181.41)
00.61.4
Synonymous OE1.22
01.21.6
LoF obs/exp: 21 / 21.9Missense obs/exp: 358 / 278.1Syn Z: -1.69
DN
0.76top 25%
GOF
0.6735th %ile
LOF
0.2485th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

86 submitted variants in ClinVar

Classification Summary

Pathogenic21
Likely Pathogenic1
VUS50
Likely Benign10
Benign2
21
Pathogenic
1
Likely Pathogenic
50
VUS
10
Likely Benign
2
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
21
0
21
Likely Pathogenic
0
0
1
0
1
VUS
0
39
11
0
50
Likely Benign
1
3
4
2
10
Benign
0
0
1
1
2
Total14238384

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

UGT2A2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Key Publications
Landmark & review papers · by relevance
PubMed
Top 1 results · since 2015Search PubMed ↗